[Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin: case report].
Interferon is an immunomodulating cytokine used to treat patients with different diseases, such as hepatitis C chronic infection. Pegylated interferon is a new type of interferon, developed to increase the half-life of the drug. Many side effects have been related to its use, including ocular toxicity and retinopathy. The most reported ocular findings are cotton-wool spots and hemorrhages located at the posterior pole and surrounding optic nerve head. We describe one case of pegylated interferon-associated retinopathy with visual loss. The patient had visual acuity improvement four weeks after discontinuation of the medication and the ocular findings became much more subtle.
Avila
Marcos Pereira de
MP
Centro Brasileiro de Cirurgia de Olhos, Goiânia (GO), Brazil.
Freitas
André Moraes
AM
Isaac
David Leonardo Cruvinel
DL
Bastos
André Luis de Moura
AL
Pena
Rafael Valadares
RV
D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced*; D012254:Ribavirin / Q000009:adverse effects*; D014792:Visual Acuity / Q000187:drug effects
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin